Clinical lymphoma, myeloma & leukemiaHumansPyridazinesMaleFemaleImidazoles
Molecular Milestones and Survival Outcomes of Ponatinib Treatment in Patients With Chronic Myeloid Leukemia and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia: A Real-World Analysis.
Tai-Chung Tseng, Yu-Sung Chang, Xavier Cheng-Hong Tsai, Ming-En Lin, Feng-Ming Tien, Huai-Hsuan Huang, Yun-Chu Lin, Jia-Hau Liu, Ming-Chih Liu, Chien-Chin Lin, Chieh-Lung Cheng, Szu-Chun Hsu, Ming Yao, Mei-Hsuan Tseng, Yen-Ling Peng
Published: 202610.1016/j.clml.2025.09.003
Abstract
BACKGROUND: Ponatinib, a third-generation tyrosine kinase inhibitor, has demonstrated its activity against chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). However, real-world data, particula…
Preview only. Read the full abstract at the source